NasdaqGM:IRONBiotechs
The Bull Case For Disc Medicine (IRON) Could Change Following Strong New Myelofibrosis Anemia Data - Learn Why
Disc Medicine recently reported positive initial data from its ongoing Phase 2 RALLY-MF trial of DISC-0974 in myelofibrosis-related anemia, showing large hepcidin reductions, improved iron levels, meaningful hemoglobin gains, and a generally well-tolerated safety profile across multiple patient groups.
A key takeaway was that DISC-0974 showed clinically meaningful anemia improvements even in patients on concomitant JAK inhibitor therapy, hinting at potential use alongside current standards...